Trading Report: Today: 12,000 Shares of Stock are sold by Insider Selling: Stryker Corp. (SYK) Director

Today: 12,000 Shares of Stock are sold by Insider Selling: Stryker Corp. (SYK) Director

Stryker Corp. (NYSE:SYK) Director Ronda E. Stryker sold 12,000 shares of the firm’s stock in a transaction dated Monday, November 28th. The stock was sold at an average price of $112.73, for a total transaction of $1,352,760.00. Following the completion of the transaction, the director now directly owns 193,142 shares in the company, valued at $21,772,897.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Stryker Corp. (NYSE:SYK) traded up 0.10% on Monday, reaching $112.95. 1,323,904 shares of the company’s stock traded hands. The firm has a market capitalization of $42.29 billion, a P/E ratio of 25.71 and a beta of 0.86. Stryker Corp. has a 52 week low of $86.68 and a 52 week high of $123.55. The stock has a 50-day moving average of $113.60 and a 200 day moving average of $115.00.

Stryker Corp. (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 27th. The medical technology company reported $1.39 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.37 by $0.02. The business had revenue of $2.83 billion for the quarter, compared to analyst estimates of $2.81 billion. Stryker Corp. had a net margin of 15.24% and a return on equity of 23.61%. The company’s revenue was up 17.1% on a year-over-year basis. During the same period in the prior year, the firm posted $1.25 EPS. On average, equities analysts expect that Stryker Corp. will post $5.78 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of SYK. Central Bank & Trust Co. raised its position in Stryker Corp. by 2.5% in the second quarter. Central Bank & Trust Co. now owns 49,387 shares of the medical technology company’s stock valued at $5,918,000 after buying an additional 1,188 shares during the last quarter. Perkins Coie Trust Co raised its position in Stryker Corp. by 2.2% in the second quarter. Perkins Coie Trust Co now owns 20,761 shares of the medical technology company’s stock valued at $2,487,000 after buying an additional 451 shares during the last quarter. Bank of Stockton raised its position in Stryker Corp. by 3.8% in the second quarter. Bank of Stockton now owns 5,356 shares of the medical technology company’s stock valued at $642,000 after buying an additional 195 shares during the last quarter. Exxonmobil Investment Management Inc. TX raised its position in Stryker Corp. by 6.6% in the second quarter. Exxonmobil Investment Management Inc. TX now owns 81,316 shares of the medical technology company’s stock valued at $9,744,000 after buying an additional 5,034 shares during the last quarter. Finally, Lau Associates LLC acquired a new position in Stryker Corp. during the second quarter valued at approximately $204,000. Hedge funds and other institutional investors own 74.90% of the company’s stock.

SYK has been the topic of a number of analyst reports. SunTrust Banks Inc. initiated coverage on shares of Stryker Corp. in a research note on Thursday, October 13th. They set a “buy” rating and a $140.00 target price on the stock. Zacks Investment Research downgraded shares of Stryker Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, September 27th. Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker Corp. in a research note on Sunday, November 13th. BMO Capital Markets raised shares of Stryker Corp. from an “underperform” rating to a “market perform” rating and set a $125.00 target price on the stock in a research note on Tuesday, November 1st. They noted that the move was a valuation call. Finally, Canaccord Genuity set a $127.00 target price on shares of Stryker Corp. and gave the stock a “buy” rating in a research note on Sunday, October 30th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $122.38.

Stryker Corp. Company Profile

Related posts

Leave a Comment